CytoSorbents Corporation Form 8-K Summary
Business Context and Reporting Period
CytoSorbents Corporation filed a Form 8-K regarding events occurring on September 22, 2026, with the report signed and press release issued on September 23, 2026. The filing concerns Nasdaq listing compliance and Regulation FD disclosure. It does not provide quarterly or annual operating results.
Key Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, cash balances, or other operating financial metrics. It states that the market value of the Company’s listed securities was below Nasdaq’s $35 million minimum requirement as of the June 29, 2026 notice. The Company may consider increasing stockholders’ equity to at least $2.5 million, but the filing does not state current equity or liquidity figures.
Material Changes Versus Prior Period
- On September 22, 2026, Nasdaq confirmed that the Company had regained compliance with the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2), and that matter was closed.
- The Company remains noncompliant with Nasdaq’s market value of listed securities requirement under Rule 5550(b)(2), which requires market value of at least $35 million.
- The Company received 180 calendar days, through December 28, 2026, to regain compliance with the market value requirement.
Outlook, Risks, and Unusual Items
To regain compliance with the market value requirement, the Company’s listed securities must have a market value of at least $35 million for a minimum of 10 consecutive business days, unless Nasdaq extends the period at its discretion. The Company is evaluating potential actions and will monitor its market value. If compliance is not restored by December 28, 2026, Nasdaq may issue a delisting notification, which the Company may appeal. The filing states that there is no assurance the Company will regain compliance or maintain its Nasdaq Capital Market listing.
Item 7.01 includes a press release furnished as Exhibit 99.1. The Regulation FD information is furnished rather than filed and is not subject to Section 18 liability or incorporation by reference into registration statements, except as otherwise specified under applicable rules.
Investor Verification Items
- Verify the Company’s current market capitalization and progress toward the $35 million Nasdaq requirement.
- Review any subsequent Nasdaq correspondence, compliance extensions, delisting notice, or appeal.
- Assess whether the Company pursues equity issuance, capital restructuring, or other actions to increase stockholders’ equity to at least $2.5 million.
- Review Exhibit 99.1 and subsequent periodic filings for financial results, cash resources, financing needs, and management commentary.